Table 3

Cox proportional hazards model for analysis of drug retention of secukinumab versus an alternative TNFi after prior exposure to one or more TNFis

MethodVariableAll patients with axSpA
N=390; Nevents=203
ASAS-positive patients with axSpA
N=252 ; Nevents=129
HR95% CIP valueHR95% CIP value
Propensity score basedSecukinumab versus TNFi1.140.78 to 1.680.501.200.74 to 1.940.47
Covariate adjustment Secukinumab versus TNFi 1.16 0.79 to 1.71 0.45 1.30 0.81 to 2.09 0.27
 Age1.011.00 to to 1.030.41
 Female versus male sex1.461.02 to to 2.270.08
 ASDAS1.280.98 to 1.680.071.391.02 to 1.890.03
 BASFI1.030.92 to 1.160.591.010.88 to 1.160.94
 BASMI0.950.80 to 1.140.600.980.76 to 1.250.84
 HLA-B27 positive versus negative1.150.82 to 1.610.420.890.58 to 1.370.59
 Enthesitis, yes versus no1.040.71 to 1.500.850.910.56 to 1.490.71
 Peripheral arthritis, yes versus no0.940.67 to 1.330.730.920.58 to 1.470.73
 Non-radiographic, versus radiographic axspA1.380.80 to 2.410.251.300.72 to 2.350.39
 Ever psoriasis, yes versus no1.180.74 to 1.880.491.070.56 to 2.050.83
 Ever uveitis, yes versus no0.800.50 to 1.270.340.930.52 to 1.670.81
 Ever inflammatory bowel disease, yes versus no0.990.55 to 1.800.981.310.62 to 2.750.47
 Current smoking, yes versus no0.970.61 to 1.530.880.770.44 to 1.350.37
 BMI ≤25 kg/m2 versus BMI >25 kg/m2 1.110.80 to 1.530.541.020.69 to 1.520.91
 Reason for discontinuation of prior
 TNFi (other vs ineffectiveness)
0.840.62 to to 1.200.29
 Later-line versus second-line bDMARDs0.950.69 to 1.310.761.070.72 to 1.590.74
  • HR for discontinuation of secukinumab versus TNFi is shown in bold as the result of main interest for both methods of analysis used (matched-weight propensity score approach and covariate-adjusted analysis, respectively).

  • ASAS, Assessment in SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; HLA-B27, human leucocyte antigen B27; TNFi, tumour necrosis factor inhibitor.